Story perspectives

Eli Lilly Surges: $17.6B Revenue Amid Diabetes Drug Success

10/30/2025

Summary

Story summary

Eli Lilly and Company (NYSE: LLY) reported strong third-quarter earnings, delivering $17.6 billion in revenue and adjusted earnings of $7.02 per share.
The diabetes treatment Mounjaro generated $6.5 billion in revenue.
The weight-loss drug Zepbound generated $3.6 billion in revenue.
Lilly faces competition from Novo Nordisk and potential pricing pressures from Medicare negotiations.
Lilly raised its full-year revenue outlook to between $63 billion and $63.5 billion.

1 of 1

Story summary

Eli Lilly and Company (NYSE: LLY) reported strong third-quarter earnings, delivering $17.6 billion in revenue and adjusted earnings of $7.02 per share.
The diabetes treatment Mounjaro generated $6.5 billion in revenue.
The weight-loss drug Zepbound generated $3.6 billion in revenue.
Lilly faces competition from Novo Nordisk and potential pricing pressures from Medicare negotiations.
Lilly raised its full-year revenue outlook to between $63 billion and $63.5 billion.